Drug intelligence / Profile preview

BVT-115959

Development stage
Phase 2
Lead developer
Sobi
Modality
Small Molecules
Administration
Oral
01

Overview

BVT-115959 is a selective adenosine A2A receptor agonist developed for the oral treatment of pain, specifically targeting peripheral sites of inflammation and injury. The drug was designed to act preferentially at lower pH values found in inflamed tissues, thereby localizing its effect to sites of injury and reducing the risk of systemic side effects. It was investigated primarily for neuropathic and inflammatory pain conditions but development was discontinued after Phase II clinical trials due to insufficient efficacy or strategic reasons. The compound originated from Cambridge Biotechnology and was further developed by Swedish Orphan Biovitrum (Biovitrum)[1][5][6][10].

Other names
2-O-methylisoguanosineadenosine 2-methoxy-adenosine2-methoxy-adenosine-2-methoxy-NSC-36899NSC36899NSC 36899
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on BVT-115959.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BVT-115959.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call